Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 1998 October;39(5) > The Journal of Cardiovascular Surgery 1998 October;39(5):551-5

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE JOURNAL OF CARDIOVASCULAR SURGERY

A Journal on Cardiac, Vascular and Thoracic Surgery


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,179


eTOC

 

ORIGINAL ARTICLES  VASCULAR PAPERS


The Journal of Cardiovascular Surgery 1998 October;39(5):551-5

Copyright © 2000 EDIZIONI MINERVA MEDICA

language: English

Thrombolysis with i.v. recombinant human tissue-type plasminogen activator in patients with bypass graft occlusion: a good adjunctive therapeutic mode (preliminary and case reports)

Agresta F., Michelet I., Boni V., Tonietto G.

From the Department of Surgery Ospedale Civile, Vittorio Veneto, Treviso, Italy


PDF  


Background and methods. The authors report their experience with thrombolytic therapy in seven cases of graft thrombosis managed successfully with low-dose I.V. rt-TPA. In six patients the cause was an anatomical one and so, after the successful lysis, there was enough time to confirm a correct diagnosis and plan the “right” and “less extensive” surgical procedure, obviating it in one case with a “functional” cause of thrombosis.
Results. No complication directly attributable to rt-TPA infusion occurred, and no systemic fibrinogenolysis was registered in any cases. Judging from this experience, I.V. rt-TPA appears safe and effective in patients with graft thrombosis, proving to be a good adjunctive therapeutic mode.
Conclusions. Further studies are needed do delineate more clearly safe indication and the validity of this method.

top of page

Publication History

Cite this article as

Corresponding author e-mail